Arbutus Biopharma Corp (ABUS)
3.46
+0.02
(+0.58%)
USD |
NASDAQ |
Nov 21, 16:00
3.46
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Revenue (Quarterly): 1.339M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.339M |
| June 30, 2024 | 1.726M |
| March 31, 2024 | 1.532M |
| December 31, 2023 | 2.145M |
| September 30, 2023 | 4.658M |
| June 30, 2023 | 4.651M |
| March 31, 2023 | 6.687M |
| December 31, 2022 | 6.245M |
| September 30, 2022 | 5.952M |
| June 30, 2022 | 14.24M |
| March 31, 2022 | 12.58M |
| December 31, 2021 | 3.206M |
| September 30, 2021 | 3.34M |
| June 30, 2021 | 2.329M |
| March 31, 2021 | 2.113M |
| December 31, 2020 | 2.386M |
| September 30, 2020 | 1.523M |
| June 30, 2020 | 1.514M |
| March 31, 2020 | 1.491M |
| December 31, 2019 | 1.618M |
| September 30, 2019 | 3.061M |
| June 30, 2019 | 0.653M |
| March 31, 2019 | 0.679M |
| December 31, 2018 | 1.678M |
| September 30, 2018 | 1.587M |
| Date | Value |
|---|---|
| June 30, 2018 | 1.244M |
| March 31, 2018 | 1.436M |
| December 31, 2017 | 2.534M |
| September 30, 2017 | 6.892M |
| June 30, 2017 | 1.039M |
| March 31, 2017 | 0.235M |
| December 31, 2016 | -0.195M |
| September 30, 2016 | 0.774M |
| June 30, 2016 | 0.309M |
| March 31, 2016 | 0.603M |
| December 31, 2015 | 11.09M |
| September 30, 2015 | 4.065M |
| June 30, 2015 | 3.44M |
| March 31, 2015 | 4.682M |
| December 31, 2014 | 4.35M |
| September 30, 2014 | 4.362M |
| June 30, 2014 | 1.811M |
| March 31, 2014 | 4.43M |
| December 31, 2013 | 7.527M |
| September 30, 2013 | 2.963M |
| June 30, 2013 | 2.844M |
| March 31, 2013 | 2.132M |
| December 31, 2012 | 3.709M |
| September 30, 2012 | 3.097M |
| June 30, 2012 | 3.559M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.339M
Minimum
Sep 2024
14.24M
Maximum
Jun 2022
4.064M
Average
2.358M
Median
Revenue (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 745.74M |
| Amicus Therapeutics Inc | 141.52M |
| Ionis Pharmaceuticals Inc | 133.81M |
| GlycoMimetics Inc | -- |
| FibroGen Inc | 46.33M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.72M |
| Total Expenses (Quarterly) | 18.81M |
| EPS Diluted (Quarterly) | -0.10 |
| Enterprise Value | 527.85M |
| Profit Margin (Quarterly) | -1.47K% |
| Earnings Yield | -12.43% |
| Normalized Earnings Yield | -11.72 |